Starling Oncology, Inc. Warrant
STLNW
25 hedge funds and large institutions have $3.42M invested in Starling Oncology, Inc. Warrant in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 5 closing their positions.
86% more capital invested
Capital invested by funds: $1.83M → $3.42M (+$1.58M)
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
14% more funds holding
Funds holding: 22 → 25 (+3)
2.35% more ownership
Funds ownership: 3.22% → 5.57% (+2.4%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRCM
Sage Rock Capital Management
New York
|
+$441K |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$439K |
| 3 |
ECM
Element Capital Management
New York
|
+$366K |
| 4 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
+$132K |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$108K |
| 2 |
OCAM
Owl Creek Asset Management
New York
|
-$85K |
| 3 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$68K |
| 4 |
KC
Kepos Capital
New York
|
-$64.7K |
| 5 |
SCM
Saba Capital Management
New York
|
-$52K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $9K | +$8.34K | +4,837 | New |
|
|
27
Marshall Wace
London,
United Kingdom
| – | -$108K | -62,492 | Closed |
|
|
OCAM
28
Owl Creek Asset Management
New York
| – | -$85K | -49,999 | Closed |
|
|
PMAM
29
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
| – | -$68K | -40,000 | Closed |
|
|
SCM
30
Saba Capital Management
New York
| – | -$52K | -24,464 | Closed |
|
31
Geode Capital Management
Boston,
Massachusetts
| – | -$20K | -12,500 | Closed |
|
STLNW Hedge Fund Activity: Q4 2020 in Review
25 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology, Inc. Warrant (STLNW) for Q4 2020, worth a combined $3.42M — up 86% from $1.83M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new STLNW positions and 5 closed out — a net gain of 3 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Sage Rock Capital Management, opening a new position worth an estimated $441K. The largest seller was Marshall Wace, exiting entirely with an estimated $108K sold.
- 25 institutional investors held Starling Oncology, Inc. Warrant (STLNW) as of Q4 2020, up from 22 in Q3 2020.
- Funds reported $3.42M of Starling Oncology, Inc. Warrant stock for Q4 2020, up 86% quarter-over-quarter.
- 8 funds opened new Starling Oncology, Inc. Warrant positions in Q4 2020 and 5 closed out, a net change of +3 holders.
- The largest Starling Oncology, Inc. Warrant buyer in Q4 2020 was Sage Rock Capital Management, an estimated $441K added.
- The largest Starling Oncology, Inc. Warrant seller in Q4 2020 was Marshall Wace, an estimated $108K sold.
Based on aggregated 13F filings for Q4 2020.